Pentoxifylline 400 MG Extended Release Oral Tablet

INDICATIONS AND USAGE Pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease.

Apotex Corp.

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] nausea` `[3] pain` `[4] drug dependence` `[5] fatigue` `[6] off label use` `[7] vomiting` `[8] headache` `[9] diarrhoea` `[10] overdose`

5 years ago

OVAL WHITE APO 033

5 years ago

APO 033 OVAL WHITE

HOW SUPPLIED

PENTOXIFYLLINE extended-release tablets, USP are available for oral administration as 400 mg white, oval, unscored, film coated tablets, imprinted “APO 033” on one side and plain on the other side; supplied in bottles of 100 (NDC 60505-0033-6), bottles of 500 (NDC 60505-0033-7), bottles of 1,000 (NDC 60505-0033-9) and bottles of 5,500 (NDC 60505-0033-8). Store at 20° to 25°C (68° to 77°F) [see Controlled Room Temperature]. Dispense in a tight, light-resistant container [see USP]. APOTEX INC.

PENTOXIFYLLINE EXTENDED-RELEASE TABLETS, USP 400mg Manufactured by Manufactured for Apotex Inc. Apotex Corp. Toronto, Ontario Weston, Florida Canada M9L 1T9 33326 Revised: May 2016 Rev. 7

More pills like OVAL APO 033

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site

Pentoxifylline 400 MG Extended Release Oral Tablet

FDA Reported Adverse Reactions [1] drug ineffective [2] nausea [3] pain [4] drug dependence [5] fatigue [6] off label use [7] vomiting [8] headache [9] diarrhoea [10] overdose

OVAL WHITE APO 033

APO 033 OVAL WHITE

More pills like OVAL APO 033

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] nausea` `[3] pain` `[4] drug dependence` `[5] fatigue` `[6] off label use` `[7] vomiting` `[8] headache` `[9] diarrhoea` `[10] overdose`